Table IV Proteomics discoveries are validated in the literature. Quantification via MSE-based proteomics shows agreement with several previously reported responses of Chlamydomonas to various metal-deficiency growth conditions
Model IDaGene nameDescriptionExperimental conditionbΔcEvidencedReference
CuRD
Cre03.g182551PCY1Plastocyanin1271 ± 200n.d.IB23
Cre16.g651050CYC6Cytochrome c6n.d.283 ± 41IB, RNA-Seq13, 23
Cre02.g085450CPX1Coprogen III oxidase94 ± 43940 ± 136IB, RNA-Seq13, 44
Cre09.g393150FOX1Ferroxidase13 ± 5n.d.IB44, 48
Cre17.g700950FDX5Ferredoxin 5n.d.7 ± 2IB, RNA-Seq13, 15
ZnRDL
Cre04.g223100CAH1Carbonic anhydrase171 ± 81n.d.n.m.qPCRUnpublished data
117458ZCP1COG0523 domainn.d.1588 ± 226n.m.qPCR21
FeRDL
Cre09.g387800FER1Pre-apoferritin22 ± 268 ± 1553 ± 11IB, qPCR16
Cre12.g546550FEA1Fe-assimilating protein124 ± 21735 ± 341356 ± 115IB, qPCR14
Cre12.g546600FEA2Fe-assimilating proteinn.d.97 ± 16512 ± 77IB, qPCR14
Cre14.g626700PETFFerredoxin87 ± 3530 ± 27n.d.IB, qPCR15
Cre06.g306350FDX3Ferredoxin 3n.d.n.d.45 ± 7IB15
Cre09.g393150FOX1Ferroxidasen.d.11 ± 125 ± 21IB48
Cre16.g676150MSD3Mn superoxide dismutasen.d.10 ± 373 ± 21A, IB, qPCR19, 20
Cre06.g257601PRX12-Cys peroxiredoxin839 ± 77834 ± 701042 ± 54SILAC, IB17
MnRDL
Cre02.g096150MSD1Mn superoxide dismutase48 ± 48n.d.n.d.A, qPCR20
Cre16.g676150MSD3Mn superoxide dismutasen.d.n.d.27 ± 3qPCR20
Cre02.g132800PSBOOxygen-evolving enhancer protein 11056 ± 2761235 ± 2981730 ± 447IB20
Cre12.g550850PSBP1Oxygen-evolving enhancer protein 21589 ± 1762296 ± 2592013 ± 817IB20
Cre08.g372450PSBQOxygen evolving enhancer protein 3655 ± 120807 ± 281788 ± 360IB20
  • Protein abundance is reported in the “Experimental Condition” column in zmol/cell.

  • n.d., not detected; n.m., not measured; ↓, decrease; ↑, increase; IB, immunoblot; A, activity; SILAC, stable isotope labeling of amino acids in cell culture.

  • a Reported by Augustus 10.2 identifiers or, if an Augustus 10.2 model does not exist, by FM3.1 identifiers.

  • b R, metal replete; D, metal deficient; L, metal limited.

  • c Response reported as the change observed in the micronutrient-deficient condition relative to the replete status.

  • d Type of evidence available.